LUND, APRIL 21, 2021:Mount Sinai has joined RhoVac’s multicenter trial of RV1001 in post-surgical and -radiotherapy patients with prostate cancer. RV1001 blocks the RhoC protein which appears to be involved in metastasis. www.rhovac.com .
Sinai joins RhoVac’s multicenter trial